Born 1988, Italian citizien, Swiss resident. He is responsible for pushing forward the core technology of Annaida. He holds a master’s degree in theoretical physics (University of Milan Bicocca, Italy), and he obtained PhD from the Swiss Federal Institute of Technology (EPFL, Lausanne CH) in microengineering and microelectronics for NMR, and is the main inventor of EmbryoSpin. He co-founded Annaida shortly after and is now focusing on product and business development.
Born 1988, US and Italian citizien, Swiss resident. He is responsible for presentations, pitching and driving public exposure efforts. He holds a master’s degree in applied phyiscs (University of Milan Statale, IT), and he obtained his PhD from the University of Fribourg (CH), developing optical methods for synthetic and biological nanomaterials. He then switched focus towards optical based microfabrication as well as project management and business development. He is co-inventor of EmbryoSpin.
Born in 1974, Belgian citizen, Swiss resident. Pascal is a co-founder and the CEO of HEMEX, a pharmaceutical, biotech and medical device consulting firm with offices in Switzerland, Germany and the USA. From 2011 to 2015, Pascal worked for Finox Biotech, bringing one of the first biosimilar fertility treatments to the market in the EU and leading to the successful acquisition by Gedeon Richter for EUR 190 million in 2016. Prior to that, Pascal worked in various positions in the pharmaceutical and medtech industry, last serving as Arpida’s Head of Documentation and Data Center, where he was leading the department responsible for collecting, managing, analyzing, and submitting large amounts of scientific and clinical data to regulatory authorities. Pascal holds a bachelor’s degree in Telecommunication Technologies (University of Leuven, Belgium) and a master’s degree in Clinical Research (Donau University in Krems, Austria). With his consulting firm HEMEX, Pascal has invested in several innovative life science startups, where he also advises on regulatory, clinical and marketing strategies, either as a senior consultant or as a board member.
Work in progress here :-)
Prof. Gardner is Group Director of ART, Scientific Innovation and Research of Virtus Health. He obtained his PhD in Embryology & Biochemistry at the University of York, UK in 1987. He became a Fellow of Cellular and Molecular Physiology at Harvard Medical School in 1988. In 1989 he moved to the Centre for Early Human Development, Monash Medical Centre. At Monash David’s laboratory developed the system for human blastocyst culture. In 1997 he became Scientific Director of the Colorado Centre for Reproductive Medicine in Denver, where he was the first in the world to introduce blastocyst culture and transfer as a clinical procedure. The Denver clinic became the most successful IVF unit in the USA. In 2007 he took up the position of Chair of Zoology at the University of Melbourne and soon became Head of the Department until the end of 2014. In 2015 he took up the position of Research Professor in the newly formed School of BioSciences. David has authored nearly 300 publications, five of which are in the 100 most cited papers in reproductive medicine and biology. He is one of the most highly cited scientists in reproductive medicine. David was elected as a Fellow of the Australian Academy of Science in May 2017 and was the recipient the 2017 Distinguished Researcher Award by the American Society for Reproductive Medicine. He is currently the President of the Alpha (International Society of Scientists in Reproductive Medicine) and leads an active research team working on embryo physiology, new embryo culture systems, the development of embryo biomarkers, and blastocyst-uterine interactions.
Biologist, Dr. of Science (PhD), ESHRE senior clinical embryologist. He graduated as a biologist at the University of Lausanne in 2002, became a Doctor of Science (PhD) in 2006 and then joined the Human Genetics Unit of the MRC in Edinburgh. In 2007, he joined the Laboratory of Reproductive Biology of the CPMA and is now head of the Fertility sector at the Medisupport group, member of the CPMA management board and chief executive officer of the Fertas laboratory. Over these years he has overseen early stage development of new IVF technologies, up to clinical trials and commercialization.
German physicist, specialized in experimental physics, fluent in English and French. He is renowned for research and development of laser products for medical applications in the fields of in vitro fertilization, tissue welding and the treatment of kidney stones. He holds a PhD from EPFL obtained in 1992 in optics of lasers. From his graduation, he continues his work developing laser systems that are today at the base of all the laser cutters used in IVF to perform embryo biopsy. In 2000 he co-founded OCTAX Microscience GmbH in Germany. OCTAX developed and manufactured IVF medical equipment, ranging from therapeutic to diagnostics appliances. OCTAX was reputed worldwide for producing the most reliable and accurate laser equipment. In 2016 Dr. Rink sold the company to Vitrolife.
Professor at the Ecole Polytechnique Federale de Lausanne (EPFL), Switzerland in Microengineering and Materials Science. Before he was at the MESA Research Institute of Nanotechnology, Netherlands, at the IBM Zurich Research Laboratory, and at the Hitachi Central Research Laboratory, Japan. He received his Master in Physical-Electronics and his PhD from Neuchatel University, Switzerland. Over 15 years of important contributions in microengineering, micro/nanofabrication, additive micro-manufacturing, new materials for MEMS for biomedical applications, with scientific publications and start-ups that have spun off from the lab.
Giovanni obtained a diploma in Physics from Genova University in 1994, worked at CERN and Fermilab from 1994 to 1996, and obtained a PhD in microengineering from EPFL in 2000. He has been since more than 20 years at EPFL where he is now senior scientist specializing in nuclear magnetic resonance, electron spin resonance, and ferromagnetic resonance methods and devices for sub-nanoliter samples. He has authored over 100 scientific articles on these topics.